search

Active clinical trials for "Fibrosis"

Results 741-750 of 3184

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients...

Cystic Fibrosis

Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi

Terminated23 enrollment criteria

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary...

Idiopathic Pulmonary FibrosisPulmonary Fibrosis4 more

The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.

Terminated16 enrollment criteria

Effect of Glycine in Cystic Fibrosis

Cystic Fibrosis

The aim of this study is to evaluate if glycine, orally administered in a daily dose of 0.5 g/kg during 8 weeks, can ameliorate the airway inflammation in children with cystic fibrosis, as compared with placebo. During all of the study children will receive their usual treatment for cystic fibrosis.

Terminated10 enrollment criteria

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

Cystic FibrosisPancreatic Insufficiency

The specific aims for this study are: To determine if sonographic findings predict the risk of progression of liver disease to cirrhosis by comparing cystic fibrosis subjects with heterogeneous echogenicity pattern on ultrasound to those with normal echogenicity pattern on ultrasound To develop a database and biorepository of serum, plasma, urine and DNA to aid the investigations in ascertaining the mechanisms, consequences, genetic risk factors and biomarkers for the development of cirrhosis To determine if there are differences in health related quality of life, pulmonary or nutritional status in children with cystic fibrosis who have a heterogeneous echo pattern on ultrasound compared to those who have a normal echo pattern on ultrasound To determine if Doppler velocity measurements of hepatic and splenic vessels predict an increased risk for the development of cirrhosis. To determine if cirrhosis on ultrasound progresses to portal hypertension during the study period To determine if homogeneous liver progresses to either cirrhosis or heterogeneous liver. To determine the frequency of complications of portal hypertension during follow up in those identified with cirrhosis by year 6 of the study

Active14 enrollment criteria

Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy

Hepatic EncephalopathyLiver Cirrhosis

Two groups of patients with minimal hepatic encephalopathy will be studied. The treatment group (n=17) will receive whole milk (24 g lactose) and the control group (n=17) will receive "lactose-free" milk (3.5 g of lactose) two times a day for 21 days. Clinical history, nutritional assessment, biochemical studies, psychometric tests, critical flicker frequency and a quality of life questionnaire will be performed. The patient will be assessed weekly 21 days. An external monitor will control the randomization process in order to allocate the patients into both study group and will not share the assignation codes with anyone until the end of the study.

Terminated12 enrollment criteria

An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated...

Cystic FibrosisAllergic Bronchopulmonary Aspergillosis

This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.

Terminated9 enrollment criteria

Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

Cystic Fibrosis

Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.

Terminated26 enrollment criteria

IGF-1 Therapy in Patients With Cystic Fibrosis

Cystic Fibrosis

28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.

Terminated16 enrollment criteria

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of...

AscitesLiver Cirrhosis

Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).

Terminated8 enrollment criteria

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of...

AscitesLiver Cirrhosis

Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites. Secondary: To evaluate the tolerability and safety of satavaptan in the absence of concomitant diuretic drugs over a 52-week treatment period in patients with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).

Terminated9 enrollment criteria
1...747576...319

Need Help? Contact our team!


We'll reach out to this number within 24 hrs